Lincoln Pharmaceuticals Ltd · NSE:LINCOLN
Lincoln Pharmaceuticals — Q1 FY2024 Earnings Presentation
24 slides from Lincoln Pharmaceuticals's earnings presentation, 2023
Slide 1: Q1 FY2024 Earnings Presentation
Q1 FY2024 PHARMACEUTICALS LTD Earnings Presentation HEALTHCARE FOR ALL GROWING IS COMMITEMENT. WE PROCESS. www.lincolnpharma.com
Slide 2: Disclaimer
Disclaimer The information, statements and analysis made in this presentation describing Company’s objectives, projections and estimates are forward looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which cou
Slide 3: Corporate Overview
Corporate Overview Background Product Portfolio Manufacturing Exports Established in the year 1979, 1700 registered products Manufacturing facility at Khatraj, Exports contribute 57.4% in FY23; Lincoln Pharma hasdeveloped and another 700 in pipeline. Ahmedabad and Mehsana, Gujarat. Domestic Sales co
Slide 4: Q1 FY24 Business Performance & Future Road Map
Q1 FY24 Business Performance & Future Road Map • Company has delivered an excellent operational and financial performance in Q1FY24 and maintained healthy growth in domestic operations, export business, profitability and margins. For Q1FY24, company reported Standalone Net Profit of Rs. 19.0 crore,
Slide 5: Q1 FY24 Standalone Results
Q1 FY24 Standalone Results TOTAL INCOME EBITDA NET PROFIT 129.9 143.3 23.4 28.4 15.0 19.0 Q1 FY23 Q1 FY24 Q1 FY23 Q1 FY24 Q1 FY23 Q1 FY24 Fig (RsCr) Q1 FY2024Earning Presentation
Slide 6: Performance – Focused Therapeutic Areas
Performance – Focused Therapeutic Areas Therapy Area Q1 FY24 Q1 FY23 General Anti Infectives 26.4% 22.5% 28.7% 26.4 29.4% 22.5% Respiratory Systems 7.7% 8.4% Alimentary Tract andMetabolism 6.8% 6.6% Genito Urinary System and Sex Hormones 1.7% 2.1% 0.2% Musculo-Skeletal System 17.9% 17.5% 0.03% Q1 FY
Slide 7: Performance Overview
Performance Overview STANDALONE FINANCIAL PERFORMANCE (Rs in Cr.) PARTICULARS Q1 Y-o-Y 12 Months Y-o-Y FY2024 FY2023 Growth (%) FY2023 FY2022 Growth (%) Total Income 143.3 129.9 10.3% 532.8 482.1 10.5% EBITDA 28.4 23.4 21.4% 111.7 105.5 5.9% Profit BeforeTax 25.5 20.9 21.6% 100.5 95.9 4.7% Profit Af
Slide 8: About Lincoln Pharmaceuticals Ltd
About Lincoln Pharmaceuticals Ltd Providing Affordable And Innovative Medicines For Healthier Lives. Vision To spark a universal attempt to uncover cures of diseases by focused and targeted R&D, through forging strategic alliances both domestically and internationally. Mission Focused on delivering
Slide 9: Key Milestones
Key Milestones 1979 1996-97 2010-11 2016-17 Listed on NSE. Domestic marketexpansion; Install 2.1 MW windmill Launched nextgeneration Received WHO-GMPfor Covered 80% of India market. in addition to 6000 progesterone therapy - plant/production unit. KVA in 2009. ProlinSpray. Lincoln wasincorporated an
Slide 10: Growth Drivers – Ready for the Next Big Leap
Growth Drivers – Ready for the Next Big Leap CAPEX Company has successfully completed expansion at Cephalosporin plan at Mehsana, Gujarat. Commercial Production from this plant has commenced. Company started selling in domestic market as well as exports. For other countries plant inspection and prod
Slide 11: Lincoln Pharmaceuticals Ltd – Financial Overview
Lincoln Pharmaceuticals Ltd – Financial Overview Year Revenue EBITDA Net Profit EPS Share Price FY 23 532.8 111.7 72.9 36.4 338.7 FY 18 367.0 57.7 34.7 17.3 210.3 5 Yrs CAGR 7.7% 14.1% 16.0% 16.0% 10.0% Book Yalue (Per Share) Market Cap (Rs Cr) Net Debt (Rs Cr) 71.1 251 678 623 216 188 450 157 425 1
Slide 12: Business Revenue Mix
Business Revenue Mix Particulars (Rs. CR) FY 2013 % FY 2017 % FY 2023 % Domestic Sales 145.03 74.50% 246.6 67.40% 217.20 42.6% Export 49.67 25.50% 119.27 32.60% 293.11 57.4% FY13 FY17 FY23 25.5% 32.6% 57.4% 42.6% 67.4% 74.5% DOMESTIC SALES EXPORT Q1 FY2024Earning Presentation
Slide 13: Global Footprints
Global Footprints Presence over 60+ countries in Europe, Canada, Latin & North America, Africa, Asia Pacific, South EastAsia, and 26 states across India. Srinagar Jammu Chandigarh Uttrakhand North America: Ambala Europe: Delhi Ghaziabad Canada. France. Lucknow Guwahati Jaipur Patna Ranchi Ahmedabad
Slide 14: Research & Development
Research & Development NDDS Formulations Introduced First Time In India by Lincoln Anti-Fungal VaginaSpray. Diclofenac RectalSpray. Sildenafil Oral Spray. Ondansetron Hydrochloride Oral Spray (DOMI-UP). Paracetamol 1000mg Programmed Release Tablet (PA-12). Micronized Progesterone Vaginal Spray (PROL
Slide 15: Innovations – Lincoln Pharma
Innovations – Lincoln Pharma Q1 FY2024Earning Presentation
Slide 16: New Launches – Domestic Market
New Launches – Domestic Market Q1 FY2024Earning Presentation
Slide 17: New Launches – International Markets
New Launches – International Markets Q1 FY2024Earning Presentation
Slide 18: Wide Spectrum of Therapeutic Coverage
Wide Spectrum of Therapeutic Coverage Cough &Cold/ Dermatologist Gyneacological Sterile Ophthalmic Gastro Intestinal Anti Allergic/ Preparation Products Eye Drops/ Range Anti-asthmatics Ointment Vitamins/ Anti-bacterial/ Anti-viral/ Analgesic/ Anti-Malarial M inerals/ Otology Anti-fungal Anti-pyreti
Slide 19: Best In Class Facilities – Khatraj, Gujarat
Best In Class Facilities – Khatraj, Gujarat Certification EU-GMP,TGA, WHO-GMP Certified; ISO 9001:2015, ISO-14001:2015 and ISO-45001:2018 Certified. R&D Center Approved by Government of India; Team of 30 plus scientists for R&D. Green Energy Windmill and 1MW Solar Roof installed. Producing 65% of co
Slide 20: Best in Class Facilities – Mehsana, Gujarat
Best in Class Facilities – Mehsana, Gujarat WHO-GMP Certified; ISO 9001:2015 Certified. Certification Approved Team of 10 plus scientists for R&D. R&D Center Dosage Forms Produced at Unit 3 OSD and Dry Powder Injection Description Size Annual Capacity Unit Tablet (Compression& Coating) 511 lacs Tabl
Slide 21: Financial Highlights
Financial Highlights TOTALINCOME NET PROFIT 532.8 72.9 69.4 482.1 62.3 428.7 396.3 51.5 FY20 FY21 FY22 FY23 FY20 FY20 FY21 FY21 FY22 FY22 FY23 EBITDA NET WORTH Fig (RsCr) 105.5 111.65 432.9 502.5 92.8 366.4 76.5 304.1 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 Q1 FY2024Earning Presentation
Slide 22: Profitability Ratios
Profitability Ratios EBITDA MARGIN PAT MARGIN 21.7% 21.9% 14.5% 14.4% 13.7% 21.0% 13.0% 19.3% FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 ROCE RONW 22.6% 16.9% 17.0% 22.0% 21.9% 16.0% 19.9% 14.5% FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 Q1 FY2024Earning Presentation
Slide 23: Share Holding Information
Share Holding Information Particulars June 2023 March 2023 Investor Category No of Shareholders No of Shares Held Holding (%) No ofShareholders No of Shares Held Holding (%) Promoter Group 27 97,49,112 48.67% 27 97,14,112 47.00% Public Holding 27,453 1,02,80,616 51.33% 29,061 1,06,15,616 53.00% Tota
Slide 24: Location
Location Corporate Office Lincoln House B/h Satyam Complex, Science City Road, Sola Ahmedabad - 380060,Gujarat, India. Phone: +91 - 79 - 4107 8000 l Fax: +91- 79 - 4107 8062 Email: info@lincolnpharma.com Web: www.lincolnpharma.com CIN: L24230GJ1995PLC024288 Darshit Shah Gopal Modi CFO, Lincoln Pharm
Lincoln Pharmaceuticals — Q1 FY2024 Earnings Presentation on 6ix